Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
The Oncologist|August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy ResultsBenjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Journal for Immunotherapy of Cancer|July 1, 2026
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinomaRana R McKay, Michael Serzan, Wanling Xie, et al.
Urologic Oncology|August 2, 2022
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinomaNishita Tripathi, Yeonjung Jo, Abhishek Tripathi, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
The Lancet. Oncology|April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 studyRamaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate CancerNeeraj Agarwal, Roberto Nussenzveig, Andrew W Hahn, et al.
European Urology Oncology|May 12, 2024
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized TherapyVinay Mathew Thomas, Nicolas Sayegh, Beverly Chigarira, et al.
BMC Cancer|April 18, 2024
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trialAdriana M Coletta, Lea Haverbeck Simon, Kelsey Maslana, et al.
JCO Precision Oncology|September 14, 2020
Pathogenic Germline DNA Repair Gene and <i>HOXB13</i> Mutations in Men With Metastatic Prostate CancerJulie L Boyle, Andrew W Hahn, Ashley L Kapron, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
The Oncologist|August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy ResultsBenjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Journal for Immunotherapy of Cancer|July 1, 2026
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinomaRana R McKay, Michael Serzan, Wanling Xie, et al.
Urologic Oncology|August 2, 2022
Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinomaNishita Tripathi, Yeonjung Jo, Abhishek Tripathi, et al.
Prostate Cancer and Prostatic Diseases|January 30, 2025
Genomic biomarkers of survival in patients with metastatic hormone-sensitive prostate cancer undergoing intensified androgen deprivation therapyGeorges Gebrael, Nicolas Sayegh, Chadi Hage Chehade, et al.
JAMA Network Open|July 18, 2024
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial CancersChadi Hage Chehade, Yeonjung Jo, Georges Gebrael, et al.
The Lancet. Oncology|April 14, 2025
Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 studyRamaprasad Srinivasan, Othon Iliopoulos, Kathryn E Beckermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate CancerNeeraj Agarwal, Roberto Nussenzveig, Andrew W Hahn, et al.
European Urology Oncology|May 12, 2024
Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized TherapyVinay Mathew Thomas, Nicolas Sayegh, Beverly Chigarira, et al.
BMC Cancer|April 18, 2024
Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trialAdriana M Coletta, Lea Haverbeck Simon, Kelsey Maslana, et al.
JCO Precision Oncology|September 14, 2020
Pathogenic Germline DNA Repair Gene and <i>HOXB13</i> Mutations in Men With Metastatic Prostate CancerJulie L Boyle, Andrew W Hahn, Ashley L Kapron, et al.
Pageof 12